My NIDDK-funded R01 and K01 projects investigate immunosuppression individualization using national transplant registries, electronic health records, and machine learning.
The R01 uses granular real-world clinical data to study both safety and efficacy. The K01 focuses on an evidence-based framework for kidney transplant recipients using national registry data.
An emerging direction is longitudinal management: using target trial emulation and causal machine learning to investigate tacrolimus dosing and tapering strategies. This is an ongoing research agenda, rather than an established clinical protocol.